Linsidomine (3-morpholinosydnonimine or SIN-1[1]) is a vasodilator. It is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection[2] in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.[citation needed]
Clinical data | |
---|---|
Other names | SIN-1 |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6H10N4O2 |
Molar mass | 170.172 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
Linsidomine is neurotoxic and promotes oxidative stress on neurons.[3] Linsidomine is a peroxynitrite-generating compound involved in the pathogenesis of neurodegenerative diseases.[4]